Pharmaceutical manufacturers face a multitude of challenges related to launching specialty and rare disease products within a complex ecosystem, finding a single source vendor for all product launch milestones, ensuring appropriate patient access and affordability of high-cost specialty medications and optimal compliance.  AscellaHealth addresses these challenges by providing end-to-end solutions including, pre-commercialization and market access, product launch, exclusive distribution, fulfillment, patient support and HUB services, and data and analytics for a streamlined path to product commercialization, and optimal therapeutic outcomes.

In the ever-evolving landscape of specialty pharmaceuticals and healthcare, AscellaHealth emerges as a trailblazer, driven by a vision to revolutionize the industry. Led by Founders, Dea Belazi and Bill Oldham, the company transcends the role of a mere player, positioning itself as a pioneer committed to driving innovation, patient-centric care, and ensuring optimal access to specialty medications for millions grappling with chronic and complex conditions worldwide.

The heart of AscellaHealth’s mission is a patient-centric approach that focuses on putting patients first with dedicated resources to address the specialized needs of patients with specialty diseases and complex, chronic conditions. AscellaHealth advances patient engagement and care compliance with a team of dedicated patient care coordinators (PCCs) who provide a human touch, with tech-enabled support that guides patients and families to adhere to treatment and individualized care plans. This compassion translates into a personalized approach tailored to each specialty patient and their specific needs, going the extra mile to ensure affordability of these costly therapies and that they are more accessible.  

As the specialty pharmacy landscape continues to evolve, AscellaHealth’s commitment to serving all industry stakeholders and patients remains the same – to improve health outcomes and optimize the journey for rare and orphan disease patients.

Empowering Manufacturers

In the realm of specialty pharmaceutical innovation, AscellaHealth is recognized as a trailblazer in ushering groundbreaking therapies, with global end-to-end solutions for life science manufacturers that span the entire product lifecycle. The organization’s role as a single-source vendor for product commercialization of specialty medications and cell and gene therapies (CGTs) to treat patients with rare or complex, chronic disease addresses the myriad of challenges faced by manufacturers.

From navigating the complex drug approval process to crafting global market access strategies, managing the exorbitant costs of specialty medications, providing superior patient care, and easing the administrative burden for pharmaceutical companies, the company successfully addresses the need for streamlined patient access to therapy with a goal that everybody who needs the therapy is able to get it.  

Combining exclusive distribution with a comprehensive range of end-to-end solutions and patient HUB services including support for limited distribution drugs (LDD), allows manufacturers to take advantage of working with one vendor throughout the entire product lifecycle and an approach that ultimately gets the product to the patient where and when the patient needs it. 

By offering a holistic suite of services, AscellaHealth aims to optimize patient access, improve outcomes, and reduce overall costs. “Our approach to patient engagement and compliance is clearly a key differentiator from competitors that simply direct individuals to website chats, call center queues or other impersonal communications. We are highly recognized for capabilities that foster patient adherence to treatment, improve patient outcomes and streamline the care journey,” adds Belazi.

Recognizing the need for a more high-touch, patient-centric approach that is grounded in “putting patients first,” truly differentiates AscellaHealth in becoming a collaborative partner to pharmaceutical manufacturers as well as other stakeholders, payers and providers.  With deep experience in managing rare diseases coupled with a commitment to managing all launch milestones position AscellaHealth as an indispensable, collaborative partner for manufacturers navigating the complex market landscape.

AscellaHealth’s personalized, flexible programs are customized to meet the unique needs of patients, pharmaceutical/life sciences partners, payers and providers, offering flexible options and innovative, proprietary solutions that can be customized and tailored to specific requirements,” extols Belazi. 

Customized Cost Containment Solutions for Payers

AscellaHealth’s commitment to payers is embedded in customizable services, accompanied by extensive specialty pharmacy and rare disease expertise that drives innovative cost-containment strategies and solutions. These innovative end-to-end solutions are designed to control specialty drug spend without compromising the quality of care for patients, as well as customized clinical programs for enhanced member outcomes. Recognized for a collaborative approach and strategic alliances designed to support payers in their opportunities for product reimbursement, AscellaHealth successfully brings potentially lifesaving therapies to health plan members. By empowering payers with actionable data, streamlined processes and innovative programs — from addressing reimbursement challenges to optimizing financial platforms — AscellaHealth stands as a dedicated partner committed to enhancing member access, reducing costs, optimizing clinical outcomes and ensuring the overall efficiency of payer operations.

Eliminating Administrative Burdens

A key focus for AscellaHealth is eliminating the administrative burdens that arise when pharmaceutical companies contract with multiple vendors. The company emphasizes the importance of a working with a one-stop resource that streamlines the complex commercialization process, allowing manufacturers to navigate the challenges seamlessly.

AscellaHealth uses a variety of strategies and techniques to enhance patient engagement, ensuring compliance with treatment plans and improving care coordination. The significance of a dedicated, personalized care team for patients and their caregivers takes center stage, emphasizing a holistic approach to patient care.

AscellaHealth recognizes the importance of leveraging data for informed decision-making and actionable results. As a single-source provider, AscellaHealth helps all partners to demonstrate long-term outcomes, providing real-world evidence that supports payers with managing specialty drug spend and early visibility into the total health system costs related to a particular disease and for pharmaceutical manufacturers, data is needed to engage in outcomes-based contracts, establish the causal relationships between the disease and outcomes while helping to reduce overall costs.

Optimizing the Supply Chain

The complexities of the specialty and rare disease medications supply chain are not overlooked. AscellaHealth acknowledges the unique handling needs of these medications, such as refrigeration, overnight delivery, and shipment tracking. The company commits to optimizing the supply chain to ensure seamless access for patients, recognizing the critical nature of timely medication delivery.

A detailed overview of AscellaHealth’s full spectrum of cutting-edge programs and services unfolds, emphasizing the benefit for all specialty pharmacy stakeholders. From rare disease patients to life science and biotechnology companies, and payers, AscellaHealth’s offerings encompass pre-commercialization, market access, distribution logistics, patient/member support services, financial pharmaceutical services, copay assistance programs, customized clinical programs for enhance member outcomes, cost containment solutions for payers, and much more.

An instance that highlights the company’s value proposition is when the team assisted a manufacturer.  The client company solicited an experienced partner for integrated branded services to assist with the launch of a third line product with a different mode of administration, in an extremely competitive market. AscellaHealth’s nationally recognized specialty pharmacy offers a full suite of comprehensive services to pharmaceutical manufacturers, tailored to maximize the therapeutic opportunities for the treatment of orphan and rare disorders. Its patient-centric services include individual care plans with outreach during key points in therapy and technology tools which support phone, email, text, and mobile apps to streamline communication and increase response rates. “AscellaHealth’s custom program developed for this manufacturer, implemented by our dedicated, branded teams, resulted in enhanced clinical outcomes and increased patient/ provider satisfaction,” explains Belazi.

Integrated Patient Services/HUB for Optimal Results

AscellaHealth’s integrated patient services and HUB model proved instrumental in achieving optimal results for a manufacturer launching a third-line product. The results highlight enhanced compliance, retention, and satisfaction rates, underscoring the effectiveness of AscellaHealth’s tailored programs.

AscellaHealth’s vision for the future is ongoing innovation and expansion, with a commitment to remaining at the forefront of the specialty pharmaceutical industry. AscellaHealth aims to scale programs globally, meeting the unique needs of a highly specialized patient population and continuing its dedication to improving health outcomes and optimizing the journey for patients facing rare diseases, chronic, or complex conditions. AscellaHealth’s story is one of resilience, innovation, and a relentless commitment to transforming lives. In a landscape where the need for patient-centric solutions is paramount, AscellaHealth stands as a beacon, illuminating a path towards a future where specialty pharmaceuticals are not just about treatments but about personalized, patient-focused care. “We are looking forward to continuing to scale our programs throughout the US, UK and Europe as an extraordinary need exists for this highly specialized patient population, especially as new therapies continue to be researched and approved. Our quest for excellence is ongoing, as we continue to devote resources toward patient-centric care and team expansion throughout the world to serve a burgeoning client base,” concludes Belazi.